Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes (ATTEND)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00950313|
Recruitment Status : Completed
First Posted : July 31, 2009
Last Update Posted : November 13, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetes||Other: Self Assessment Other: Electronic risk score||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||432 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Assessment of Response Rates and Yields for Two Tools for Early Detection of Non-diabetic Hyperglycaemia and Diabetes|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||July 2014|
|Actual Study Completion Date :||July 2014|
Active Comparator: Self Assessment
Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
Other: Self Assessment
Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
Active Comparator: Electronic risk score
Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
Other: Electronic risk score
Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
- Increase in response rates to invitation to 2nd stage blood test [ Time Frame: 12 months ]
- Increase in yield of OGTT positive results through filtering of high risk participants that pass 1st and 2nd stage screens [ Time Frame: 12 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00950313
|Leicester City PCT|
|Leicester, Leicestershire, United Kingdom|
|Principal Investigator:||Kamlesh Khunti, MD||University of Leicester|